Akebia Therapeutics, Inc. (NASDAQ:AKBA)‘s stock had its “hold” rating reiterated by investment analysts at Royal Bank Of Canada in a research report issued on Thursday. They presently have a $17.00 price objective on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price suggests a potential downside of 6.34% from the stock’s current price.

Several other equities research analysts also recently issued reports on AKBA. HC Wainwright reiterated a “buy” rating and issued a $24.00 target price on shares of Akebia Therapeutics in a research note on Wednesday, August 9th. Zacks Investment Research upgraded shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. BidaskClub upgraded shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. Mizuho began coverage on shares of Akebia Therapeutics in a research report on Wednesday, October 4th. They set a “buy” rating and a $24.00 price objective for the company. Finally, ValuEngine upgraded shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $20.63.

Akebia Therapeutics (NASDAQ:AKBA) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.89) by $0.36. The firm had revenue of $28.52 million during the quarter, compared to analyst estimates of $26.50 million.

ILLEGAL ACTIVITY NOTICE: “Royal Bank Of Canada Reiterates Hold Rating for Akebia Therapeutics, Inc. (AKBA)” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/02/royal-bank-of-canada-reiterates-hold-rating-for-akebia-therapeutics-inc-akba.html.

In related news, SVP Michel Dahan sold 1,398 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $19.64, for a total value of $27,456.72. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders sold 12,586 shares of company stock worth $222,289. 7.95% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in AKBA. American International Group Inc. raised its holdings in shares of Akebia Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 22,121 shares of the biopharmaceutical company’s stock valued at $204,000 after purchasing an additional 1,460 shares during the period. Wellington Management Group LLP grew its position in Akebia Therapeutics by 17.4% in the 1st quarter. Wellington Management Group LLP now owns 152,020 shares of the biopharmaceutical company’s stock worth $1,399,000 after purchasing an additional 22,520 shares in the last quarter. Vanguard Group Inc. grew its position in Akebia Therapeutics by 8.8% in the 1st quarter. Vanguard Group Inc. now owns 1,301,880 shares of the biopharmaceutical company’s stock worth $11,977,000 after purchasing an additional 105,645 shares in the last quarter. Geode Capital Management LLC grew its position in Akebia Therapeutics by 4.7% in the 1st quarter. Geode Capital Management LLC now owns 330,096 shares of the biopharmaceutical company’s stock worth $3,036,000 after purchasing an additional 14,959 shares in the last quarter. Finally, UBS Group AG grew its position in Akebia Therapeutics by 79.0% in the 1st quarter. UBS Group AG now owns 151,646 shares of the biopharmaceutical company’s stock worth $1,395,000 after purchasing an additional 66,948 shares in the last quarter. Hedge funds and other institutional investors own 58.73% of the company’s stock.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.